Krystal Biotech Reports Positive KB113 Data in Gorlin Syndrome Patients
Krystal Biotech said KB113 demonstrated broad basal cell carcinoma regression in patients with Gorlin syndrome.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Krystal Biotech Reports Positive KB113 Data in Gorlin Syndrome
The company announced clinical data showing broad basal cell carcinoma regression in patients with Gorlin syndrome.